| 袁晓红,李 鹏,胡彦超,李雨微,刘军辉.rh-BNP联合阿托伐他汀治疗急性心梗后心衰的临床疗效及对患者血清cTn-I、Myo、CK-MB水平的影响[J].,2019,19(19):3776-3779 |
| rh-BNP联合阿托伐他汀治疗急性心梗后心衰的临床疗效及对患者血清cTn-I、Myo、CK-MB水平的影响 |
| Clinical efficacy of Intravenous rh-bnp Combined with Atorvastatin in the Treatment of Heart Failure after Acute Myocardial Infarction and Its Effect on the Serum Levels of cTn-I, Myo and CK-MB |
| 投稿时间：2019-05-07 修订日期：2019-05-31 |
| DOI：10.13241/j.cnki.pmb.2019.19.041 |
| 中文关键词: 静脉注射 重组人脑利钠肽 阿托伐他汀 急性心梗后心衰 心肌肌钙蛋白 肌红蛋白 肌酸激酶同工酶 |
| 英文关键词: Intravenous Recombinant human brain natriuretic peptide Atorvastatin Heart failure after acute myocardial infarction Cardiac troponin Myoglobin Creatine kinase isoenzyme |
| 基金项目:陕西省自然科学基金项目(20131623) |
|
| 摘要点击次数: 468 |
| 全文下载次数: 504 |
| 中文摘要: |
| 摘要 目的：研究重组人脑利钠肽（rh-BNP）联合阿托伐他汀治疗急性心梗后心衰的临床效果及对患者血清心肌肌钙蛋白（cardiac troponin，cTn-I）、肌红蛋白（Myoglobin，Myo）、肌酸激酶同工酶（CK-MB）水平的影响。方法：选择我院2017年2月~2019年1月收治的72例急性心梗后心衰患者，按随机数字表法分为观察组38例，对照组34例。对照组给予阿托伐他汀治疗，观察组在对照组基础上另加rh-BNP，观察和比较两组的临床疗效，治疗前后血清cTn-I、Myo、CK-MB水平的变化及治疗后不良反应的发生情况。结果：治疗后，观察组总有效率明显高于对照组(P<0.05)，血清cTn-I、Myo、CK-MB水平均显著低于对照组[(0.23±0.10) vs. (0.16±0.08)、(27.54 ±3.86) vs. (21.62 ±2.54)、(70.82±9.25) vs. (61.28±8.33)](P<0.05)。观察组治疗后不良反情况总发生率为7.89%，明显低于对照组(26.47%，P<0.05)。结论：与单用阿托伐他汀治疗相比，静脉注射rh-BNP联合阿托伐他汀治疗急性心梗后心衰可显著提高临床疗效和安全性，有效减低血清cTn-I、Myo、CK-MB水平。 |
| 英文摘要: |
| ABSTRACT Objective: To study Clinical efficacy of Intravenous rh-bnp Combined with Atorvastatin in the Treatment of Heart Failure after Acute Myocardial Infarction and Its Effect on the Serum Levels of Myocardial troponin (cardiac troponin, cTn-I), Myoglobin (Myoglobin, Myo), creatine kinase isoenzyme (CK-MB). Methods: 72 patients with heart failure after acute myocardial infarction admitted to our hospital from February 2017 to January 2019 were selected, were divided into observation group 38 cases and control group 34 cases according to random number table method. The control group was treated with atorvastatin, and rh-bnp was added to the observation group on the basis of the control group to observe and compare the clinical efficacy of the two groups, the changes of serum ctn-i, Myo and ck-mb levels before and after treatment, and the occurrence of adverse reactions after treatment. Results: After treatment, the total effective rate of the observation group was significantly higher than that of the control group (P<0.05), and the serum levels of ctn-i, Myo and ck-mb were significantly lower than those of the control group [(0.23±0.10) vs (0.16±0.08), (27.54 ±3.86) vs (21.62 ±2.54), (70.82±9.25) vs (61.28±8.33)](P<0.05). The overall incidence of adverse reactions after treatment in the observation group was 7.89%, significantly lower than that in the control group (26.47%, P<0.05). Conclusion: Compared with atorvastatin alone, intravenous rh-bnp combined with atorvastatin in the treatment of heart failure after acute myocardial infarction can significantly improve the clinical efficacy and safety, and effectively reduce serum levels of ctn-i, Myo and ck-mb. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
